Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELx MP test to diagnose 12 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone763-392-0767
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees26
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable
Celcuity (NASDAQ:CELC) Frequently Asked Questions
What is Celcuity's stock symbol?
Celcuity trades on the NASDAQ under the ticker symbol "CELC."
How were Celcuity's earnings last quarter?
Celcuity Inc (NASDAQ:CELC) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.02. View Celcuity's Earnings History.
When is Celcuity's next earnings date?
What price target have analysts set for CELC?
1 analysts have issued twelve-month target prices for Celcuity's stock. Their forecasts range from $36.00 to $36.00. On average, they expect Celcuity's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 262.5% from the stock's current price. View Analyst Price Targets for Celcuity.
What is the consensus analysts' recommendation for Celcuity?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celcuity.
Has Celcuity been receiving favorable news coverage?
News stories about CELC stock have trended negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celcuity earned a news sentiment score of -2.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Celcuity.
Are investors shorting Celcuity?
Celcuity saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 45,200 shares, an increase of 134.2% from the January 15th total of 19,300 shares. Based on an average daily trading volume, of 13,100 shares, the days-to-cover ratio is currently 3.5 days. Currently, 0.9% of the shares of the company are sold short. View Celcuity's Current Options Chain.
Who are some of Celcuity's key competitors?
Some companies that are related to Celcuity include Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), OpGen (OPGN), Cancer Genetics (CGIX) and First Choice Healthcare Solutions (FCHS).
What other stocks do shareholders of Celcuity own?
Who are Celcuity's key executives?
Celcuity's management team includes the folowing people:
- Mr. Brian F. Sullivan, Co-Founder, Chairman & CEO (Age 57)
- Dr. Lance G. Laing, Co-Founder, Chief Science Officer, VP, Sec. & Director (Age 57)
- Ms. Vicky Hahne, Chief Financial Officer (Age 53)
- Ms. Laura Beggrow RN, Chief Commercial Officer (Age 56)
- Mr. Larry Fitzgerald, VP of Strategic Partnerships & Managed Markets (Age 48)
When did Celcuity IPO?
(CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.
Who are Celcuity's major shareholders?
Celcuity's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (0.84%), Punch & Associates Investment Management Inc. (0.70%), US Bancorp DE (0.35%), Renaissance Technologies LLC (0.34%), Accredited Investors Inc. (0.28%) and State of New Jersey Common Pension Fund D (0.15%). View Institutional Ownership Trends for Celcuity.
Which major investors are selling Celcuity stock?
CELC stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, UBS Group AG, US Bancorp DE and Punch & Associates Investment Management Inc.. View Insider Buying and Selling for Celcuity.
Which major investors are buying Celcuity stock?
CELC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Zebra Capital Management LLC, Accredited Investors Inc., Barclays PLC, State Street Corp and Northwestern Mutual Wealth Management Co.. View Insider Buying and Selling for Celcuity.
How do I buy shares of Celcuity?
Shares of CELC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Celcuity's stock price today?
One share of CELC stock can currently be purchased for approximately $9.93.
How big of a company is Celcuity?
Celcuity has a market capitalization of $101.80 million. The company earns $-7,480,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Celcuity employs 26 workers across the globe.View Additional Information About Celcuity.
What is Celcuity's official website?
How can I contact Celcuity?
Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company can be reached via phone at 763-392-0767.
MarketBeat Community Rating for Celcuity (NASDAQ CELC)
MarketBeat's community ratings are surveys of what our community members think about Celcuity and other stocks. Vote "Outperform" if you believe CELC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELC will underperform the S&P 500 over the long term. You may vote once every thirty days.
